4,901 trials
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole — 732; 1756 nanogram per milliliter (ng/mL)
Breast Cancer
Primary: Dose-Escalation Phase: Percentage of Participants With Dose-limiting Toxicity (DLTs) — 16.7; 0.0 percentage of participants
Advanced Solid Tumors, Neoplasms, Advanced Solid
Primary: Part A: Cmax: Maximum Observed Plasma and Whole Blood Concentration for Pevonedistat — 234.3; 6862.9 nanogram per milliliter (ng/mL)
Tuberculosis · Tuberculosis, Pulmonary
Primary: Number of Participants With Grade 2 or Higher Adverse Events Over the Course of the 26 Day Trial — 1; 0; 1; 1 Participants
Allergic Rhinoconjunctivitis
Primary: Number and Seriousness of Both Local and Systemic Adverse Reactions — 2; 1; 0; 1 adverse reactions number
Metastatic or Locally Advanced Cancer
Primary: Part 1. Mean Change From Baseline in Rate-Corrected (Fridericia's) QT Interval (QTcF) at 0.5 Hours — 419.23; 418.08; 1.42; 1.90 milliseconds (msec)
Bioequivalence
Primary: Androxal Cmax Formulation A — 0.999; 1.67 ng/mL
Pediatric Patients With Acute Lymphoblastic Leukemia
Primary: Local Reactions After Each Vaccination — 12; 7; 14; 9 Participants
Healthy
Primary: Peak Plasma Concentration (Cmax) of ASP2151 — 1818.0; 1202.3; 3573.1; 2452.1 ng/mL
Adhesion
Primary: Number of Participants With Adverse Events (AEs) — 16; 17 Participants
Inhalational Anthrax
Primary: Number of Participants Who Experienced Adverse Events — 5; 3; 1; 1 Participants
Pharmacokinetics
Primary: Cmax of Proellex — 485.6; 876.7; 912.9; 1322.5 ng/mL
Healthy
Primary: Maximum Measured Concentration of the Hyoscine Butylbromide in Plasma (Cmax) — 70.3; 77.1 Picogram/millilitre [pg/mL]
Prostate Cancer
Primary: Percentage of Participants Who Required Study Drug Dose Reduction During Treatment Periods 1 and 2 — 4.5; 0.0 percentage of participants
Solid Malignancies
Primary: Total Radioactivity in Plasma Following Administration of [14C]-AZD2014 — 4013; 3415; 2901; 2693 nanogram equivalent/millilitre (ngEq/mL)